Skip to ContentSkip to Navigation
About us Latest news News

€2 million ERC Grant for research on modulating the gut microbiome to improve drug efficacy

09 December 2020

Dr. Jingyuan Fu of the UMCG Genetics/Paediatrics departments has received an ERC Consolidator Grant of € 2 million from the EU. She will use this to investigate whether the effectiveness of medicines can be improved by making adjustments to the whole of micro-organisms in the gastrointestinal system (intestinal microbiome). Her research focuses mainly on commonly used medication that patients receive with cardiovascular diseases or with psychiatric disorders. Her research will take 5 years.

Dr. Fu, Photo: Elmer Spaargaren
Dr. Fu, Photo: Elmer Spaargaren

A large number of patients do not respond well to commonly used drugs; some patients suffer from side effects. In Europe, about 3.5% of hospital admissions are related to side effects of medicines. It means that many patients are not treated properly because they do not respond or respond poorly to medicines. This not only has consequences for the patient’s well-being, but also entails enormous clinical and financial burdens.

With this ERC Consolidator Grant, Dr. Jingyuan Fu solve this problem by changing the bacteria that live in the intestines of humans. In this BugDrug project she will focus on 23 drugs, which are widely used in the treatment of cardiometabolic and psychiatric disorders. She made this choice because these are common chronic diseases that require patients to take medication on a daily basis. Examples of these medications are statins, beta blockers or ACE inhibitors.

The BugDrug project is based on a very new concept that the gut bacteria can contribute to a better individual response to medicines. Altering the gut microbiome may open up the possibility of making existing drugs work again. In her research, Jingyuan Fu uses the large LifeLines cohort study, innovative organ-on-a-chip technology and clinical interventions. It is precisely through this combination that she hopes to achieve a better prediction of the response to medicines and a greater effectiveness of the medication. This research is believed to pave the way for designing the next phase of personalized medicine, by taking into account an individual’s genetics and gut microbiome.

The ERC Consolidator Grant is intended for researchers who completed their thesis 7-12 years ago. They must have since built up a promising scientific status and submitted an excellent research proposal.

Last modified:09 December 2020 4.45 p.m.
printView this page in: Nederlands

More news

  • 15 June 2021

    From ‘closed’ science to Open Science

    Vera Heininga is the Open Science coordinator and future programme leader of the upcoming Open Science programme of the University of Groningen. Together with her colleagues, she created the Open Science Community Groningen (OSCG). She explains...

  • 17 May 2021

    ‘Encouraging young people, that’s my most important job’

    Four and a half years ago, he received the Nobel Prize. During the award ceremony in Stockholm, Ben Feringa made a resolution: I will put science on the map. His mission is being given a new boost with the establishment of the Ben Feringa Fund,...

  • 10 May 2021

    ‘Give people with dementia more freedom to organize their own social lives’

    Older people with memory problems who live at home are extraordinarily resourceful when it comes to staying in control of their activities outside the home. Demographers Jodi Sturge and Mirjam Klaassens are certainly impressed. ‘It’s not about...